Company intelligence / Profile preview
ProNeurogen
Tucson, Arizona, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
ProNeurogen is developing PNA5, a peptide derivative of angiotensin 1-7 designed as a neuroprotective therapy for cognitive impairment in vascular dementia and Alzheimer’s disease–related conditions; current work described in public sources is pre-clinical and translational, supported in part by NIH funding, with no completed clinical trial results yet disclosed.[1][2][4][5]
- Therapeutic areas
- Neurology
- Modalities
- PeptidesSmall molecule
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on ProNeurogen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProNeurogen.